openPR Logo
Press release

Wilson Disease - Pipeline Insight, 2025: Advancing Therapies Targeting Copper Metabolism to Redefine Disease Management | DelveInsight

07-02-2025 09:32 PM CET | Health & Medicine

Press release from: DelveInsight

Wilson Disease Pipeline

Wilson Disease Pipeline

Wilson disease, a rare autosomal recessive disorder caused by mutations in the ATP7B gene, leads to abnormal copper accumulation in the liver, brain, and other organs. As current treatments like chelators and zinc therapy often come with long-term adherence challenges and side effects, the therapeutic landscape is shifting toward targeted and disease-modifying interventions.

DelveInsight's "Wilson Disease - Pipeline Insight, 2025" highlights a dynamic pipeline with over 5+ investigational therapies in development, focusing on novel mechanisms such as copper-protein binding agents, gene therapy, and ATP7B modulators. Notable players, including Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics, are driving innovation to improve efficacy, reduce toxicity, and address unmet needs in both pediatric and adult patient populations.

With programs progressing through various clinical stages, the report provides comprehensive insights into trial design, target mechanisms, regulatory progress, and strategic collaborations. These pipeline candidates aim not only to normalize copper levels but also to prevent hepatic and neurological damage, shifting the paradigm toward early intervention and long-term management.

The evolving pipeline underscores the growing recognition of Wilson disease as a treatable metabolic disorder and represents a promising era for precision therapies that could significantly improve patient outcomes and quality of life.

Interested in learning more about the current treatment landscape and the key drivers shaping the Wilson Disease pipeline? Click here: https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Wilson Disease Pipeline Report
• DelveInsight's Wilson Disease pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for Wilson Disease treatment.
• The leading Wilson Disease companies include Vivet Therapeutics, Depymed, Prime Medicine, Deep Genomics, and others are evaluating their lead assets to improve the Wilson Disease treatment landscape.
• Key Wilson Disease pipeline therapies in various stages of development include VTX-801, DPM 1001, Research Programme Hepatolenticular Degeneration Gene Therapies, DG 12P1, and others.
• In June 2025, the FDA has accepted GSK's New Drug Application (NDA) for linerixibat (IBAT inhibitor), targeting cholestatic pruritus in primary biliary cholangitis (PBC).
• In May 2025, the FDA released a safety alert warning that patients stopping long-term use of prescription (and OTC) antihistamines cetirizine (Zyrtec) or levocetirizine (Xyzal) may experience rare but severe itching, also known as pruritus, appearing within days of discontinuation.
• In April 2025, the FDA approved a tablet formulation of maralixibat for cholestatic pruritus in patients with Alagille syndrome (ALGS) (≥3 months old) and PFIC (≥12 months old).

Request a sample and discover the recent breakthroughs happening in the Wilson Disease pipeline landscape at https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Wilson Disease Overview
Wilson disease is a rare, inherited disorder characterized by the body's inability to properly eliminate excess copper. Caused by mutations in the ATP7B gene, it leads to the accumulation of copper in vital organs such as the liver, brain, and eyes, resulting in hepatic, neurological, and psychiatric symptoms. If left untreated, Wilson disease can cause severe liver damage, neurological dysfunction, and even death.

Typically presenting between childhood and early adulthood, the condition is often misdiagnosed due to its varied symptoms. Early diagnosis through genetic testing, serum ceruloplasmin levels, and 24-hour urinary copper excretion is crucial for effective management. Current treatment involves lifelong use of copper-chelating agents like penicillamine or trientine, and zinc therapy to block copper absorption. However, newer therapies are being explored to improve safety, adherence, and long-term outcomes.

With growing awareness and advancements in diagnostics and therapeutics, the management of Wilson disease is entering a new era focused on precision and early intervention.

Find out more about Wilson Disease medication at https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Wilson Disease Treatment Analysis: Drug Profile
VTX-801 - Vivet Therapeutics

VTX-801 is an investigational gene therapy developed by Vivet Therapeutics for the treatment of Wilson Disease. It is based on a recombinant adeno-associated virus (rAAV) vector engineered to deliver a miniaturized version of the ATP7B gene. This gene encodes a functional protein that helps restore copper balance, reverse liver damage, and reduce copper accumulation in the brain, as demonstrated in preclinical mouse models. The rAAV serotype used in VTX-801 was specifically chosen for its ability to effectively target human liver cells. VTX-801 has received Orphan Drug Designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Commission (EC), as well as Fast Track designation from the FDA. It is currently in Phase I/II clinical development.

Learn more about the novel and emerging Wilson Disease pipeline therapies at https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Wilson Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Wilson Disease Pipeline Report
• Coverage: Global
• Key Wilson Disease Companies: Vivet Therapeutics, Depymed, Prime Medicine, Deep Genomics, and others.
• Key Wilson Disease Pipeline Therapies: VTX-801, DPM 1001, Research Programme Hepatolenticular Degeneration Gene Therapies, DG 12P1, and others.

Dive deep into rich insights for drugs used for Wilson Disease treatment, visit: https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Wilson Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Wilson Disease Pipeline Therapeutics
6. Wilson Disease Pipeline: Late-Stage Products (Phase III)
7. Wilson Disease Pipeline: Mid-Stage Products (Phase II)
8. Wilson Disease Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Wilson Disease - Pipeline Insight, 2025: Advancing Therapies Targeting Copper Metabolism to Redefine Disease Management | DelveInsight here

News-ID: 4090236 • Views:

More Releases from DelveInsight

Candidiasis Clinical Trials Analysis 2025: Oral Agents, Next-Generation Echinocandins, and Broad-Spectrum Antifungals Targeting Recurrent and Invasive Disease | DelveInsight
Candidiasis Clinical Trials Analysis 2025: Oral Agents, Next-Generation Echinoca …
DelveInsight's "Candidiasis - Clinical Trials Analysis, 2025" examines an active clinical landscape addressing both mucosal (vulvovaginal) and invasive candidiasis. Unmet needs for safe, oral, and resistance-resilient therapies have driven the development of therapies across multiple modalities - new oral triterpenoids and azoles for recurrent vulvovaginal candidiasis (RVVC), next-generation echinocandins for candidemia/invasive candidiasis, and first-in-class broad-spectrum agents for drug-resistant and systemic infections. Regulatory progress and late-stage trials over the past few
Necrotizing Enterocolitis Clinical Trials Analysis 2025: Probiotics, HMOs, and Regenerative Therapies Advance Prevention and Care | DelveInsight
Necrotizing Enterocolitis Clinical Trials Analysis 2025: Probiotics, HMOs, and R …
DelveInsight's "Necrotizing Enterocolitis (NEC) - Clinical Trials Analysis, 2025" highlights an evolving pipeline aimed at reducing NEC incidence and severity in preterm infants. With NEC remaining a leading cause of neonatal morbidity and mortality, clinical studies are shifting toward microbiome-based prevention, human milk-derived biologics, and regenerative approaches. Probiotic regimens containing Bifidobacterium and Lactobacillus strains are showing consistent efficacy in lowering NEC rates and mortality, driving wider adoption in NICUs. Parallel trials
Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and Minimally Invasive Evacuation Strategies Advance Acute Care | DelveInsight
Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and …
DelveInsight's "Brain Hemorrhage - Clinical Trials Analysis, 2025" surveys an active acute-care landscape focused on reducing hematoma expansion, limiting secondary injury, and improving functional recovery after intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Trials increasingly pursue rapid hemostatic agents, targeted neuroprotectants, and device-based minimally invasive clot evacuation to shorten disability and lower mortality. Hemostatic and anti-expansion strategies (reversal agents, factor concentrates, and novel transferrable hemostats) aim to stabilize patients early and
Cachexia Clinical Trials Analysis 2025: Metabolic Modulators, Anabolic Therapies, and Anti-inflammatory Approaches Aim to Restore Mass and Function | DelveInsight
Cachexia Clinical Trials Analysis 2025: Metabolic Modulators, Anabolic Therapies …
DelveInsight's "Cachexia - Clinical Trials Analysis, 2025" examines a diverse development landscape targeting the complex metabolic, inflammatory, and neurohormonal drivers of cancer- and disease-related wasting. Given cachexia's strong association with poor survival, treatment intolerance, and reduced quality of life, trials increasingly measure both anabolic endpoints (lean body mass, muscle strength) and patient-centered outcomes (physical function, fatigue, appetite). Late-stage and registration-enabling programs span ghrelin agonists and appetite stimulants, selective androgen receptor modulators

All 5 Releases


More Releases for Wilson

Babette Wilson Soars to Success as Bestselling Author
Image: https://www.globalnewslines.com/uploads/2025/04/51e4257228e3e0b3f206786ca0c2eea4.jpg Renowned author Babette continues to captivate audiences worldwide with her thought-provoking novels. Her latest book, Quiet Suffering, The Tangled Web of a Functional Addict has catapulted her to the top of the charts, solidifying her position as a bestselling author. Babette's journey to literary success is marked by dedication, perseverance, and an unwavering commitment to telling stories that resonate deeply with readers. In Quiet Suffering , she delves into the
Wilson Disease Drugs Market Future Prediction Report By 2037
The global Wilson disease drugs market was valued at approximately USD 652.08 million in 2024 and is anticipated to reach USD 1.12 billion by 2037, reflecting a compound annual growth rate (CAGR) of over 4.3% during the forecast period from 2025 to 2037. Wilson Disease Drugs Market Overview The Wilson disease drugs market has been experiencing notable growth, driven by increasing awareness and diagnosis of this rare genetic disorder. Advancements
Corporate Training Services Market Is Booming Worldwide | Wilson Learning Worldw …
Corporate Training Services Market: The extensive research on Corporate Training Services Market, by Qurate Research is a clear representation on all the essential factors that are expected to drive the market considerably. Thorough study on Corporate Training Services Market helps the buyers of the report, customers, the stakeholders, business owners, and stockholders to understand the market in detail. The updated research report comprises key information on the market, such as
Tennis Racquet Strings Market Wilson, Babolat, HEAD
UpMarketResearch offers a latest published report on Global Tennis Racquet Strings Market industry analysis and forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains XX pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Tennis Racquet Strings Market research report delivers a close watch on leading competitors with strategic analysis,
Tennis Apparel and Footwear 2017 Global Market by Types, Countries, Manufacturer …
Tennis Apparel and Footwear Market 2017 Report Details: Wiseguyreports.Com Adds “Tennis Apparel and Footwear Market - Market Size, Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Global Tennis Apparel and Footwear market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including NIKE Adidas Wilson HEAD LiNing Prince Champion Yonex Kappa Babolat Dunlop Flia Decathlon
Global Volleyball Market- Train, Under Armour, Tachikara, Wilson
Global Volleyball Market report 2017 is an in-depth research on the current situation of the Volleyball industry. The Scope of the Volleyball research report: The Global Volleyball Market primarily includes a basic overview of the Volleyball industry. It also includes Volleyball definitions, classifications and applications. It segments the market by applications, types, regions, competitive players and also analyzes Volleyball market size, business share and Volleyball revenue, price and sales. The report mainly